
Claims

1. A compound of the formula I, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them,



I

wherein

A is chosen from the series consisting of C(R^1) and N;

D is chosen from the series consisting of C(R^2) and N;

E is chosen from the series consisting of C(R^3) and N;

L is chosen from the series consisting of C(R^4) and N;
where at least one and at most two of A, D, E or L is N;

G is chosen from the series consisting of R^{71}-O-C(O)-, R^{72}-N(R^{73})-C(O)- and tetrazol-5-yl;

R^1 is chosen from the series consisting of hydrogen, halogen, (C_1-C_6)-alkyl, HO-, (C_1-C_6)-alkyl-O-, (C_1-C_6)-alkyl-S(O)$_m$- and NC-;

R^2 is chosen from the series consisting of hydrogen, halogen, (C_1-C_7)-alkyl, (C_1-C_6)-alkyl-O-, (C_1-C_6)-alkyl-CO-, (C_1-C_6)-alkyl-CO-HN-, -$NR^{12}R^{13}$, Het^2, (C_3-C_7)-cycloalkyl-C_sH_{2s}- and Ar-C_sH_{2s}-, wherein s is an integer chosen from the series consisting of 0, 1, 2 and 3;

R^3 is chosen from the series consisting of hydrogen, halogen, $(C_1$-$C_6)$-alkyl, $(C_1$-$C_6)$-alkyl-$S(O)_m$-, Het^4-$(O)_t$-, $-NR^{12}R^{13}$, Het^2, R^{11}-O-, R^{12}-$N(R^{13})$-C(O)-O- and Het^2-C(O)-O- and NC-, wherein s is an integer chosen from the series consisting of 0, 1, 2 and 3 and wherein t is an integer chosen from the series consisting of 0 and 1;

R^4 is chosen from the series consisting of hydrogen, halogen, $(C_1$-$C_6)$-alkyl, $(C_1$-$C_6)$-alkyl-O-, HO-, $NR^{12}R^{13}$, Het^2;

R^{10} is chosen from the series consisting hydrogen, halogen, $(C_1$-$C_6)$-alkyl, $(C_1$-$C_6)$-alkyl-O-, $(C_1$-$C_6)$-alkyl-$S(O)_m$-, HO-, $-NR^{12}R^{13}$, Het^2, phenyl-C_sH_{2s}-$(O)_t$-, wherein s is an integer chosen from the series consisting of 0, 1, 2 and 3 and wherein t is an integer chosen from the series consisting of 0 and 1;

or R^1 and R^2 or R^2 and R^3 or form pyridyl;
or R^1 and R^2 are –C($(C_1$-$C_3)$-alkyl)=N-N($(C_1$-$C_3)$-alkyl)-;
or R^2 and R^3 are –NH-CH=N-;

with the proviso that one of R^1, R^2, R^3, R^4 or R^{10} is a cyclic substituent;

R^{11} is chosen from the series consisting of hydrogen, R^{14}, $(C_3$-$C_7)$-cycloalkyl, Ar and Het^3;

R^{12} and R^{13} are independently of each other chosen from the series consisting of hydrogen and R^{15};

R^{14} is $(C_1$-$C_{10})$-alkyl which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, HO-, R^{16}-O-, oxo, $(C_3$-$C_7)$-cycloalkyl, Ar, Het^1, Het^3, NC-, H_2N-C(O)-, $(C_1$-$C_4)$-alkyl-NH-C(O)-, di($(C_1$-$C_4)$-alkyl)N-C(O)-, Het^1-C(O)-, $(C_1$-$C_4)$-alkyl-C(O)-NH- and $(C_1$-$C_4)$-alkyl-$S(O)_m$-;

R^{15} is $(C_1\text{-}C_6)$-alkyl which is optionally substituted by one or more identical or different substituents chosen from the series consisting halogen, HO- and $(C_1\text{-}C_6)$-alkyl-O-;

R^{16} is $(C_1\text{-}C_6)$-alkyl which is optionally substituted by one or more identical or different substituents chosen from the series consisting of HO-, $(C_1\text{-}C_4)$-alkyl-O- and NC-;

R^{30} is chosen from the series consisting of R^{31}, $(C_3\text{-}C_7)$-cycloalkyl, $R^{32}\text{-}C_uH_{2u}$- and $Het^3\text{-}C_uH_{2u}$-, wherein u is an integer chosen from the series consisting of 0, 1, 2 and 3;

R^{31} is $(C_1\text{-}C_{10})$-alkyl which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, $(C_3\text{-}C_7)$-cycloalkyl, HO-, $(C_1\text{-}C_6)$-alkyl-O-, $(C_1\text{-}C_6)$-alkyl-$S(O)_m$- and NC-;

R^{32} is chosen from the series consisting of phenyl and an aromatic 5-membered or 6-membered monocyclic heterocycle which comprises one, two or three identical or different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, wherein the phenyl and the heterocycle all are optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, $(C_1\text{-}C_6)$-alkyl, $(C_3\text{-}C_7)$-cycloalkyl, R^{33}, HO-, $(C_1\text{-}C_6)$-alkyl-O-, R^{33}-O-, R^{33}-$(C_1\text{-}C_4)$-alkyl-O-, -O-CH_2-O-, -O-CF_2-O-, $(C_1\text{-}C_6)$-alkyl-$S(O)_m$-, H_2N-$S(O)_2$-, $(C_1\text{-}C_4)$-alkyl-NH-$S(O)_2$-, di($(C_1\text{-}C_4)$-alkyl)N-$S(O)_2$-, H_2N-, $(C_1\text{-}C_6)$-alkyl-NH-, di($(C_1\text{-}C_6)$-alkyl)N-, Het^1, $(C_1\text{-}C_4)$-alkyl-C(O)-NH-, Ar-C(O)-NH-, $(C_1\text{-}C_4)$-alkyl-$S(O)_2$-NH- and NC-;

R^{33} is chosen from the series consisting of phenyl and an aromatic 5-membered or 6-membered monocyclic heterocycle which comprises one, two or three identical or different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, wherein the phenyl and the heterocycle all are optionally substituted by one or more identical or different substituents

chosen from the series consisting of halogen, (C_1-C_6)-alkyl, (C_3-C_7)-cycloalkyl, HO-, (C_1-C_6)-alkyl-O-, (C_1-C_6)-alkyl-$S(O)_m$-, $H_2N-S(O)_2$-, (C_1-C_4)-alkyl-NH-$S(O)_2$-, di((C_1-C_4)-alkyl)N-$S(O)_2$- and NC-;

R^{40} is chosen from the series consisting of hydrogen and (C_1-C_4)-alkyl;

or R^{30} and R^{40} together are $(CH_2)_x$ which is optionally substituted by one or more identical or different (C_1-C_4)-alkyl substituents, wherein x is an integer chosen from the series consisting of 2, 3, 4 and 5;

R^{50} is chosen from the series consisting of hydrogen, (C_1-C_6)-alkyl, HO- and (C_1-C_6)-alkyl-O-;

R^{60} is chosen from the series consisting of hydrogen and (C_1-C_6)-alkyl;

or R^{50} and R^{60} together are $(CH_2)_y$ which is optionally substituted by one or more identical or different (C_1-C_4)-alkyl substituents, wherein y is an integer chosen from the series consisting of 2, 3, 4 and 5;

R^{71} is chosen from the series consisting of hydrogen and (C_1-C_8)-alkyl which is optionally substituted by one or more identical or different substituents chosen from the series consisting (C_1-C_6)-alkyl-O- and (C_1-C_6)-alkyl-C(O)-O-;

R^{72} is chosen from the series consisting of hydrogen, (C_1-C_6)-alkyl, (C_3-C_6)-cycloalkyl, $-CH_2-(CH_2)_b-(C_3-C_6)$-cycloalkyl, Het^4 and $-(CH_2)_b-Het^4$, where alkyl or cycloalkyl is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, HO-, HOOC-, (C_1-C_6)-alkyl-O- and (C_1-C_6)-alkyl-C(O)-O-, NC-, $N((C_1-C_4)$-alkyl$)_2$ and b is 0, 1 or 2;
R^{73} is chosen from the series consisting of hydrogen, (C_1-C_6)-alkyl;
or
R^{72} and R^{73} together with the nitrogen atom to which they are bonded form a saturated 4-membered to 7-membered monocyclic heterocycle, which contain

optionally one further ring heteroatom chosen from the series consisting of nitrogen, oxygen and sulfur, which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, $(C_1$-$C_4)$-alkyl, HO- and $(C_1$-$C_4)$-alkyl-O-;

Ar, independently of each other group Ar, is chosen from the series consisting of phenyl and an aromatic 5-membered or 6-membered monocyclic heterocycle which comprises one, two or three identical or different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, wherein the phenyl and the heterocycle all are optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, $(C_1$-$C_6)$-alkyl, HO-$(C_1$-$C_6)$-alkyl, Het^4, -$(CH_2)_x$-Phenyl, $(C_1$-$C_6)$-alkyl-O-, $(C_3$-$C_7)$-cycloalkyl-$(CH_2)_x$-O-, $-CF_3$, -CO-$(C_1$-$C_6)$-alkyl, $-NR^{12}R^{13}$, Het^2, $-CO-NR^{12}R^{13}$, CO-Het^2, $(C_1$-$C_6)$-alkyl-$S(O)_m$-, H_2N-$S(O)_2$- and NC-;
and wherein phenyl may be substituted by -CH=CH-CH=CH-, -O-CH_2-O-, -O-CH_2-CH_2-O-, -O-CF_2-O- or -N($(C_1$-$C_3)$-alkyl)-CH=CH-;

Het^1, independently of each other group Het^1, is a saturated or unsaturated 4-membered to 8-membered monocyclic heterocycle which comprises a ring nitrogen atom via which Het^1 is bonded and optionally one or two identical or different further ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur, which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, $(C_1$-$C_4)$-alkyl, HO-, $(C_1$-$C_4)$-alkyl-O-, oxo and NC-;

Het^2 is a saturated 4-membered to 7-membered monocyclic heterocycle which comprises a ring nitrogen atom via which Het^2 is bonded and optionally one further ring heteroatom chosen from the series consisting of nitrogen, oxygen and sulfur, which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, $(C_1$-$C_4)$-alkyl, HO- and $(C_1$-$C_4)$-alkyl-O-;

Het^3, independently of each other group Het^3, is a saturated 4-membered to 7-membered monocyclic heterocycle which comprises one or two identical or different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, which is optionally substituted by one or more identical or different substituents chosen from the series consisting of fluorine, (C_1-C_4)-alkyl and oxo;

Het^4, independently of each other group Het^4, is a saturated or unsaturated 4-membered to 8-membered monocyclic heterocycle which comprises one to four ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (C_1-C_4)-alkyl, HO-, (C_1-C_4)-alkyl-O-, oxo and NC-;

m, independently of each other number m, is an integer chosen from the series consisting of 0, 1 and 2;

wherein all cycloalkyl groups, independently of each other, are optionally substituted by one or more identical or different substituents chosen from the series consisting of fluorine and (C_1-C_4)-alkyl;

wherein all alkyl, C_sH_{2s}, C_uH_{2u}, $(CH_2)_x$ and $(CH_2)_y$ groups, independently of each other, and independently of any other substituents, are optionally substituted by one or more fluorine substituents.

2. A compound of the formula I, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, as claimed in claim 1, wherein G is chosen from the series consisting of R^{71}-O-C(O)- and R^{72}-N(R^{73})-C(O)-;
R^{30} is R^{32}-C_uH_{2u}-, wherein u is an integer chosen from the series consisting of 0 and 1;

R^{32} is chosen from the series consisting of phenyl and an aromatic 6-membered monocyclic heterocycle which comprises one or two nitrogen atoms as ring heteroatoms, wherein the phenyl and the heterocycle all are optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, $(C_1\text{-}C_6)$-alkyl, $(C_3\text{-}C_7)$-cycloalkyl, R^{33}, HO-, $(C_1\text{-}C_6)$-alkyl-O-, R^{33}-O-, R^{33}-$(C_1\text{-}C_4)$-alkyl-O-, -O-CH_2-O-, -O-CF_2-O-, $(C_1\text{-}C_6)$-alkyl-$S(O)_m$-, di($(C_1\text{-}C_4)$-alkyl)N-$S(O)_2$-, H_2N-, di($(C_1\text{-}C_6)$-alkyl)N-, Het^1, $(C_1\text{-}C_4)$-alkyl-C(O)-NH-, Ar-C(O)-NH- and NC-;

R^{33} is chosen from the series consisting of phenyl and an aromatic 6-membered monocyclic heterocycle which comprises one or two nitrogen atoms as ring heteroatoms, wherein the phenyl and the heterocycle all are optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, $(C_1\text{-}C_6)$-alkyl, $(C_3\text{-}C_7)$-cycloalkyl, HO-, $(C_1\text{-}C_6)$-alkyl-O-, $(C_1\text{-}C_6)$-alkyl-$S(O)_m$-, H_2N-$S(O)_2$-, di($(C_1\text{-}C_4)$-alkyl)N-$S(O)_2$- and NC-;

R^{40} is hydrogen.

3. A compound of the formula I, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, as claimed in any one or more of claims 1 and 2, wherein

G is R^{71}-O-C(O)-;

R^{30} is R^{32}-C_uH_{2u}-, wherein u is 0;


R^{32} is chosen from the series consisting of phenyl, wherein the phenyl is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, $(C_1\text{-}C_6)$-alkyl, $(C_3\text{-}C_7)$-cycloalkyl, R^{33}, HO-, $(C_1\text{-}C_6)$-alkyl-O-, R^{33}-O-, R^{33}-$(C_1\text{-}C_4)$-alkyl-O-, -O-CH_2-O-, -O-CF_2-O-, $(C_1\text{-}C_6)$-alkyl-$S(O)_m$-, di($(C_1\text{-}C_4)$-alkyl)N-$S(O)_2$-, H_2N-, di($(C_1\text{-}C_6)$-alkyl)N-, Het^1, $(C_1\text{-}C_4)$-alkyl-C(O)-NH-, Ar-C(O)-NH- and NC-;

R^{33} is chosen from the series consisting of phenyl, wherein the phenyl is optionally substituted by one or more identical or different substituents chosen from the series


consisting of halogen, (C_1-C_6)-alkyl, (C_3-C_7)-cycloalkyl, HO-, (C_1-C_6)-alkyl-O-, (C_1-C_6)-alkyl-$S(O)_m$-, $H_2N-S(O)_2$-, di$((C_1-C_4)$-alkyl)$N-S(O)_2$- and NC-;
R^{40} is hydrogen.

4. A compound of the formula I, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, as claimed in any one or more of claims 1 to 3, wherein
R^{50} is hydrogen;
R^{60} is hydrogen.


5. A compound of the formula I, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, as claimed in any one or more of claims 1 to 4, wherein formula I is selected from the series of subformulae I-1 to I-7




I-1




I-2




I-3




I-4



I-5




I-6



I-7

6. A compound of the formula I-1, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, as claimed in claim 5, wherein



I-1

R^2 is Ar-C_sH_{2s}-, wherein s is an integer chosen from the series consisting of 0;
R^3 is chosen from the series consisting of hydrogen, halogen, R^{11}-O-, HO-, (C_1-C_6)-alkyl and (C_1-C_6)-alkyl-O-; preferred HO- and(C_1-C_6)-alkyl
R^4 is hydrogen;
R^{10} is hydrogen.

7. A compound of the formula I, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, as claimed in claim 5 or 6, wherein

R^3 is R^{11}-O-, wherein R11 is hydrogen or (C_1-C_{10})-alkyl.

8. A compound of the formula I, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, as claimed in any one or more of claims 5 to 7, wherein

R^3 is -O-CH_3.

9. A compound of the formula I, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, as claimed in any one or more of claims 1 to 8, chosen from

(S)-3-[(5-Methoxy-6-phenyl-pyridine-2-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-(2,4-Dichloro-phenyl)-3-[(5-methoxy-6-phenyl-pyridine-2-carbonyl)-amino]-propionic acid

(S)-3-[(6-Chloro-5-methoxy-pyridine-2-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-{[3-(4,6-Dimethoxy-pyrimidin-2-yloxy)-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-[(6-Bromo-5-methoxy-pyridine-2-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-{[4-(Pyrimidin-2-ylsulfanyl)-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-[(6-Phenyl-pyridine-2-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-[(5-Phenyl-pyridine-2-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-{[5-(2-Chloro-phenyl)-pyridine-3-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[5-(2,3-Dichloro-phenyl)-pyridine-3-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[5-(2,3-Dimethyl-phenyl)-pyridine-3-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-o-Tolyl-3-[(6-m-tolyl-pyridine-2-carbonyl)-amino]-propionic acid

(S)-3-{[6-(2-Chloro-phenyl)-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[6-(2-Fluoro-phenyl)-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[6-(2,3-Difluoro-phenyl)-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[6-(2,5-Difluoro-phenyl)-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[6-(4-Fluoro-2-methyl-phenyl)-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[6-(2,3-Dimethyl-phenyl)-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[6-(5-Fluoro-2-methyl-phenyl)-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[6-(2-Methoxy-4-trifluoromethyl-phenyl)-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[6-(4-Chloro-2-methoxy-phenyl)-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[6-(2-Fluoro-5-methoxy-phenyl)-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[6-(2-Fluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[6-(2-Fluoro-5-methyl-phenyl)-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-[(5-Methoxy-6-phenyl-pyridine-2-carbonyl)-amino]-3-p-tolyl-propionic acid

(S)-3-[(5-Methoxy-6-o-tolyl-pyridine-2-carbonyl)-amino]-3-p-tolyl-propionic acid

(S)-3-{[5-Methoxy-6-(2-trifluoromethyl-phenyl)-pyridine-2-carbonyl]-amino}-3-p-tolyl-propionic acid

(S)-3-{[6-(3-Fluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-p-tolyl-propionic acid

(S)-3-{[5-Methoxy-6-(2-methoxy-phenyl)-pyridine-2-carbonyl]-amino}-3-p-tolyl-propionic acid

(S)-3-{[6-(2-Chloro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-p-tolyl-propionic acid

(S)-3-{[6-(2-Fluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-p-tolyl-propionic acid

(S)-3-{[6-(2,4-Difluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-p-tolyl-propionic acid

(S)-3-{[6-(2,3-Dichloro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-p-tolyl-propionic acid

(S)-3-{[6-(2-Chloro-5-trifluoromethyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-p-tolyl-propionic acid

(S)-3-{[6-(3-Fluoro-2-methyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-(2-fluoro-phenyl)-propionic acid

(S)-3-{[6-(2-Chloro-5-trifluoromethyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-(2-fluoro-phenyl)-propionic acid

(S)-3-{[6-(2,3-Difluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-p-tolyl-propionic acid

(S)-3-{[6-(2,5-Difluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-p-tolyl-propionic acid

(S)-3-{[6-(2,5-Dichloro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-p-tolyl-propionic acid

(S)-3-{[6-(3,5-Dimethyl-isoxazol-4-yl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-p-tolyl-propionic acid

(S)-3-{[6-(4-Fluoro-2-methyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-p-tolyl-propionic acid

(S)-3-{[6-(2,3-Dimethyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-p-tolyl-propionic acid

(S)-3-[(3,2'-Dimethoxy-[2,3']bipyridinyl-6-carbonyl)-amino]-3-p-tolyl-propionic acid

(S)-3-{[6-(5-Fluoro-2-methyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-p-tolyl-propionic acid

(S)-3-{[6-(4-Fluoro-2-methoxy-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-p-tolyl-propionic acid

(S)-3-{[6-(5-Fluoro-2-methoxy-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-p-tolyl-propionic acid

(S)-3-{[6-(2-Fluoro-5-methyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-p-tolyl-propionic acid

(S)-3-{[6-(3-Chloro-2-methyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-p-tolyl-propionic acid

(S)-3-{[6-(3-Fluoro-2-methyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-p-tolyl-propionic acid

(S)-3-{[6-(5-Chloro-2-fluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-p-tolyl-propionic acid

(S)-3-(2-Fluoro-phenyl)-3-[(5-methoxy-6-phenyl-pyridine-2-carbonyl)-amino]-propionic acid

(S)-3-{[6-(2,4-Dichloro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-(2-fluoro-phenyl)-propionic acid

(S)-3-(2-Fluoro-phenyl)-3-[(5-methoxy-6-o-tolyl-pyridine-2-carbonyl)-amino]-propionic acid

(S)-3-(2-Fluoro-phenyl)-3-{[5-methoxy-6-(2-trifluoromethyl-phenyl)-pyridine-2-carbonyl]-amino}-propionic acid

(S)-3-(2-Fluoro-phenyl)-3-{[5-methoxy-6-(2-methoxy-phenyl)-pyridine-2-carbonyl]-amino}-propionic acid

(S)-3-{[6-(2-Chloro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-(2-fluoro-phenyl)-propionic acid

(S)-3-(2-Fluoro-phenyl)-3-{[6-(2-fluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-propionic acid

(S)-3-{[6-(2,4-Difluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-(2-fluoro-phenyl)-propionic acid

(S)-3-{[6-(2,3-Dichloro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-(2-fluoro-phenyl)-propionic acid

(S)-3-{[6-(2,3-Difluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-(2-fluoro-

phenyl)-propionic acid

(S)-3-{[6-(2,5-Difluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-(2-fluoro-phenyl)-propionic acid

(S)-3-{[6-(4-Fluoro-2-methyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-(2-fluoro-phenyl)-propionic acid

(S)-3-{[6-(3,5-Dimethyl-isoxazol-4-yl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-(2-fluoro-phenyl)-propionic acid

(S)-3-{[6-(2,3-Dimethyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-(2-fluoro-phenyl)-propionic acid

(S)-3-[(3,2'-Dimethoxy-[2,3']bipyridinyl-6-carbonyl)-amino]-3-(2-fluoro-phenyl)-propionic acid

(S)-3-{[6-(5-Fluoro-2-methyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-(2-fluoro-phenyl)-propionic acid

(S)-3-{[6-(4-Fluoro-2-methoxy-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-(2-fluoro-phenyl)-propionic acid

(S)-3-{[6-(5-Fluoro-2-methoxy-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-(2-fluoro-phenyl)-propionic acid

(S)-3-{[6-(2-Fluoro-5-methyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-(2-fluoro-phenyl)-propionic acid

(S)-3-{[6-(3-Chloro-2-methyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-(2-fluoro-phenyl)-propionic acid

(S)-3-{[6-(5-Chloro-2-fluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-(2-fluoro-phenyl)-propionic acid

(S)-3-{[6-(3-Chloro-2-fluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-(2-fluoro-phenyl)-propionic acid

(S)-3-(2-Fluoro-phenyl)-3-{[5-methoxy-6-(2-methyl-furan-3-yl)-pyridine-2-carbonyl]-amino}-propionic acid

(S)-3-{[6-(2-Chloro-3-methyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-(2-fluoro-phenyl)-propionic acid

(S)-3-(2-Chloro-phenyl)-3-[(5-methoxy-6-phenyl-pyridine-2-carbonyl)-amino]-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(2,4-dichloro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(4-fluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-propionic acid

(S)-3-{[5-Methoxy-6-(3-trifluoromethyl-phenyl)-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[6-(2,4-Dichloro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[6-(4-Fluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[6-(4-Chloro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-[(5-Methoxy-6-p-tolyl-pyridine-2-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-{[6-(3-Chloro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[5-Methoxy-6-(2-methoxy-phenyl)-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-[(5-Methoxy-6-m-tolyl-pyridine-2-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-{[6-(2-Chloro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[6-(3,4-Difluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[6-(2,5-Difluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[6-(2,5-Dichloro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[6-(3,5-Dimethyl-isoxazol-4-yl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[6-(2,3-Dimethyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[6-(2,4-Dimethyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-o-tolyl-

propionic acid

(S)-3-{[6-(4-Fluoro-2-methoxy-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[6-(2-Chloro-5-methyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-(2-Chloro-phenyl)-3-[(6-methoxy-5-o-tolyl-pyridine-3-carbonyl)-amino]-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[5-methoxy-6-(2-methoxy-phenyl)-pyridine-2-carbonyl]-amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-[(5-methoxy-6-m-tolyl-pyridine-2-carbonyl)-amino]-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(2-chloro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(2-fluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(2,4-difluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(2,3-dichloro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(2,3-difluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(2,5-difluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(4-fluoro-2-methyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(2,3-dimethyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-[(3,2'-dimethoxy-[2,3']bipyridinyl-6-carbonyl)-amino]-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(5-fluoro-2-methyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(4-fluoro-2-methoxy-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-propionic acid

(S)-3-{[6-(4-Chloro-2-methoxy-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-(2-chloro-phenyl)-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(5-fluoro-2-methoxy-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(2-fluoro-5-trifluoromethyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-propionic acid

(S)-3-{[5-Methoxy-6-(2-trifluoromethyl-phenyl)-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[6-(2,4-Difluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[6-(4-Fluoro-2-methyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-[(3,2'-Dimethoxy-[2,3']bipyridinyl-6-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-[(3'-Fluoro-3-methoxy-[2,4']bipyridinyl-6-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-{[5-Methoxy-6-(2-methyl-furan-3-yl)-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[6-(4-Cyano-2-fluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(2-fluoro-5-methoxy-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(2-fluoro-5-methyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-propionic acid

(S)-3-{[6-(3-Chloro-2-methyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-(2-chloro-phenyl)-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(3-fluoro-2-methyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-propionic acid

(S)-3-{[6-(5-Chloro-2-fluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-(2-chloro-phenyl)-propionic acid

(S)-3-(2-Chloro-phenyl)-3-[(3'-fluoro-3-methoxy-[2,4']bipyridinyl-6-carbonyl)-amino]-propionic acid

(S)-3-(2-Chloro-phenyl)-3-[(5-methoxy-6-pyrazin-2-yl-pyridine-2-carbonyl)-amino]-propionic acid

(S)-3-{[6-(3-Chloro-2-fluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-(2-chloro-phenyl)-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[5-methoxy-6-(2-methyl-furan-3-yl)-pyridine-2-carbonyl]-amino}-propionic acid

(S)-3-{[6-(2-Chloro-3-fluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-(2-chloro-phenyl)-propionic acid

(S)-3-{[6-(2-Chloro-3-methyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-(2-chloro-phenyl)-propionic acid

3-Biphenyl-4-yl-3-[(6-chloro-pyridine-2-carbonyl)-amino]-propionic acid

(S)-3-[(6-Chloro-pyridine-2-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-[(3,5-Diamino-6-chloro-pyrazine-2-carbonyl)-amino]-3-o-tolyl-propionic acid

3-Biphenyl-4-yl-3-[(3,5-diamino-6-chloro-pyrazine-2-carbonyl)-amino]-propionic acid

(S)-3-{[6-(2-Fluoro-phenyl)-pyridine-2-carbonyl]-amino}-3-phenyl-propionic acid

(S)-3-(3-Fluoro-phenyl)-3-{[6-(2-fluoro-phenyl)-pyridine-2-carbonyl]-amino}-propionic acid

(S)-3-(2-Fluoro-phenyl)-3-{[6-(2-fluoro-phenyl)-pyridine-2-carbonyl]-amino}-propionic acid

(S)-3-(4-Fluoro-phenyl)-3-{[6-(2-fluoro-phenyl)-pyridine-2-carbonyl]-amino}-propionic acid

3-(2-Chloro-phenyl)-3-[(6-methoxy-quinoline-2-carbonyl)-amino]-propionic acid

(S)-3-[(6-Methoxy-biphenyl-3-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-{[6-(2-Chloro-phenyl)-pyridine-2-carbonyl]-amino}-3-m-tolyl-propionic acid

(S)-3-{[6-(2-Fluoro-phenyl)-pyridine-2-carbonyl]-amino}-3-(4-methoxy-phenyl)-propionic acid

(S)-3-{[6-(2-Chloro-phenyl)-pyridine-2-carbonyl]-amino}-3-(2-fluoro-phenyl)-propionic acid

(S)-3-{[6-(2-Chloro-phenyl)-pyridine-2-carbonyl]-amino}-3-(4-fluoro-phenyl)-propionic acid

(S)-3-(3-Chloro-phenyl)-3-{[6-(2-fluoro-phenyl)-pyridine-2-carbonyl]-amino}-propionic acid

(S)-3-(4-Chloro-phenyl)-3-{[6-(2-fluoro-phenyl)-pyridine-2-carbonyl]-amino}-propionic acid

(S)-3-(4-Chloro-phenyl)-3-{[6-(2-chloro-phenyl)-pyridine-2-carbonyl]-amino}-propionic acid

(S)-3-(3-Chloro-phenyl)-3-{[6-(2-chloro-phenyl)-pyridine-2-carbonyl]-amino}-propionic acid

3-(2-Chloro-phenyl)-3-{[6-(2-chloro-phenyl)-pyridine-2-carbonyl]-amino}-propionic acid

(S)-3-{[6-(2-Fluoro-phenyl)-pyridine-2-carbonyl]-amino}-3-(3-trifluoromethyl-phenyl)-propionic acid

(S)-3-{[6-(2-Chloro-phenyl)-pyridine-2-carbonyl]-amino}-3-(2,4-dichloro-phenyl)-propionic acid

(S)-3-{[6-(2-Chloro-phenyl)-pyridine-2-carbonyl]-amino}-3-(4-trifluoromethyl-phenyl)-propionic acid

(S)-3-{[6-(2-Chloro-phenyl)-pyridine-2-carbonyl]-amino}-3-(3-trifluoromethyl-phenyl)-propionic acid

(S)-3-{[6-Bromo-5-(3,3-dimethyl-2-oxo-butoxy)-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid.

10. A compound of the formula I, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, as claimed in any one or more of claims 1 to 8, chosen from

(S)-3-[(5-Methoxy-6-phenyl-pyridine-2-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-{[6-(2,3-Dimethyl-phenyl)-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[6-(2-Chloro-phenyl)-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[6-(2-Fluoro-phenyl)-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[6-(5-Fluoro-2-methyl-phenyl)-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-o-Tolyl-3-[(6-m-tolyl-pyridine-2-carbonyl)-amino]-propionic acid

(S)-3-({6-[3-(1-Hydroxy-1-methyl-ethyl)-phenyl]-pyridine-2-carbonyl}-amino)-3-o-tolyl-propionic acid

(S)-3-(2,4-Dichloro-phenyl)-3-[(5-methoxy-6-phenyl-pyridine-2-carbonyl)-amino]-propionic acid

(S)-3-[(2,6-Dimethoxy-pyrimidine-4-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-[(5-Phenyl-pyridine-2-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-{[3-(4,6-Dimethoxy-pyrimidin-2-yloxy)-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[4-(Pyrimidin-2-ylsulfanyl)-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[5-(2,3-Dichloro-phenyl)-pyridine-3-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[5-(2,3-Dimethyl-phenyl)-pyridine-3-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[5-(2-Chloro-phenyl)-pyridine-3-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[6-(2,3-Difluoro-phenyl)-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[6-(2-Fluoro-5-methoxy-phenyl)-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[6-(2-Fluoro-5-methyl-phenyl)-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[6-(2-Methoxy-4-trifluoromethyl-phenyl)-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-({5-Methoxy-6-[3-(5-methyl-[1,3,4]oxadiazol-2-yl)-phenyl]-pyridine-2-carbonyl}-amino)-3-o-tolyl-propionic acid

(S)-3-(2-Chloro-phenyl)-3-[(5-methoxy-6-naphthalen-2-yl-pyridine-2-carbonyl)-amino]-propionic acid

(S)-3-(2-Chloro-phenyl)-3-[(5-methoxy-6-pyrazin-2-yl-pyridine-2-carbonyl)-amino]-propionic acid

(S)-3-(2-Chloro-phenyl)-3-[(6-methoxy-5-naphthalen-2-yl-pyridine-3-carbonyl)-amino]-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[5-methoxy-6-(2-methyl-furan-3-yl)-pyridine-2-carbonyl]-amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(2,3-dimethyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(2-chloro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-propionic acid

(S)-3-(2-Fluoro-phenyl)-3-{[5-methoxy-6-(1,3,5-trimethyl-1H-pyrazol-4-yl)-pyridine-2-carbonyl]-amino}-propionic acid

(S)-3-(2-Fluoro-phenyl)-3-{[5-methoxy-6-(1-methyl-1H-indol-5-yl)-pyridine-2-carbonyl]-amino}-propionic acid

(S)-3-[(5-Methoxy-6-m-tolyl-pyridine-2-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-{[6-(2-Chloro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[6-(3,5-Dimethyl-isoxazol-4-yl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[6-(4-Chloro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid


(S)-3-{[6-(4-Chloro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-p-tolyl-propionic acid

(S)-3-{[6-(5-Acetyl-thiophen-2-yl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-(2-chloro-phenyl)-propionic acid

(S)-3-{[6-(2-Fluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid

11. A process for the preparation of a compound of the formula I or a physiologically acceptable salt thereof or a physiologically solvate of any of them as claimed in any

one or more of claims 1 to 10, comprising reacting a compound of the formula II with a compound of the formula III,



II III I

wherein the groups A, D, E, L, G, R^{10}, R^{30}, R^{40}, R^{50} and R^{60} in the compounds of the formulae II and III are defined as in the compounds of the formula I and additionally functional groups can be present in protected form or in the form of a precursor group, and the group J in the compound of the formula II is HO-, (C_1-C_4)-alkyl-O- or halogen.

12. A compound of the formula I as claimed in any one or more of claims 1 to 10 or a physiologically acceptable salt thereof or a physiologically acceptable solvate of any of them for use as a pharmaceutical.

13. A pharmaceutical composition, which comprises at least one compound of the formula I as claimed in any one or more of claims 1 to 10 or a physiologically acceptable salt thereof or a physiologically acceptable solvate of any of them and a pharmaceutically acceptable carrier.


14. Use of a compound of the formula I as claimed in any one or more of claims 1 to 10 or a physiologically acceptable salt thereof or a physiologically acceptable solvate of any of them for the manufacture of a medicament for the treatment of heart failure, congestive heart failure, cardiomyopathy, myocardial infarction, left ventricular dysfunction, cardiac hypertrophy, valvular heart diseases, hypertension, atherosclerosis, peripheral arterial occlusive disease, restenosis, vasvular permeability disorders, treatment of edema, thrombosis, rheumatoid arthritis, osteoarthritis, renal failure, cystic fibrosis, chronic bronchitis, chronic obstructive pulmonary disease, asthma, immunological diseases, diabetic complications, fibrotic

diseases, pain, ischemia or reperfusion damage or neurodegenerative diseases, or for cardioprotection or renoprotection or as a diuretic (stand-alone treatment or in combination with established diuretics).

CLAIMS

The invention claimed is:

1. A compound of the formula I, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them,



I

wherein

A is selected from the group consisting of C(R^1) and N;

D is selected from the group consisting of C(R^2) and N;

E is C(R^3);

L is selected from the group consisting of C(R^4) and N;

wherein one of A, D, and L is N;

G is selected from the group consisting of R^{71}—O—C(O)—, R^{72}—N(R^{73})—C(O)— and tetrazol-5-yl;

R^1 is selected from the group consisting of hydrogen, halogen, (C_1-C_6)-alkyl, HO—, (C_1-C_6)-alkyl-O—, (C_1-C_6)-alkyl-S(O)$_m$— and NC—;

R^2 is selected from the group consisting of hydrogen, halogen, (C_1-C_7)-alkyl, (C_1-C_6)-alkyl-O—, (C_1-C_6)-alkyl-CO—, (C_1-C_6)-alkyl-CO—HN—, —$NR^{12}R^{13}$, Het^2 (C_3-C_7)-cycloalkyl-C_sH_{2s}— and Ar—C_sH_{2s}—, wherein s is 0, 1, 2 or 3;

R^3 is R^{11}—O—;

R^4 is selected from the group consisting of hydrogen, halogen, (C_1-C_6)-alkyl, (C_1-C_6)-alkyl-O—, HO—, $NR^{12}R^{13}$, and Het^2;

R^{10} is selected from the group consisting of hydrogen, halogen, $(C_1\text{-}C_6)$-alkyl, $(C_1\text{-}C_6)$-alkyl-O—, $(C_1\text{-}C_6)$-alkyl-$S(O)_m$—, HO—, —$NR^{12}R^{13}$, Het^2, and phenyl-C_sH_{2s}—$(O)_t$—, wherein s is 0, 1, 2 or 3, and t is 0 or 1;

with the proviso that one of R^1, R^2, R^4 or R^{10} is a cyclic substituent;

R^{11} is selected from the group consisting of hydrogen, R^{14}, $(C_3\text{-}C_7)$-cycloalkyl, Ar and Het^3;

R^{12} and R^{13} are independently selected from the group consisting of hydrogen and R^{15};

R^{14} is $(C_1\text{-}C_{10})$-alkyl, which is optionally substituted by one or more identical or different substituents selected from the group consisting of halogen, HO—, R^{16}—O—, oxo, $(C_3\text{-}C_7)$-cycloalkyl, Ar, Het^1, Het^3, NC—, H_2N—C(O)—, $(C_1\text{-}C_4)$-alkyl-NH—C(O)—, di$((C_1\text{-}C_4)$-alkyl)N—C(O)—, Het^1-C(O)—, $(C_1\text{-}C_4)$-alkyl-C(O)—NH— and $(C_1\text{-}C_4)$-alkyl-$S(O)_m$—;

R^{15} is $(C_1\text{-}C_6)$-alkyl which is optionally substituted by one or more identical or different substituents selected from the group consisting of halogen, HO— and $(C_1\text{-}C_6)$-alkyl-O—;

R^{16} is $(C_1\text{-}C_6)$-alkyl which is optionally substituted by one or more identical or different substituents selected from the group consisting of HO—, $(C_1\text{-}C_4)$-alkyl-O— and NC—;

R^{30} is selected from the group consisting of R^{31}, $(C_3\text{-}C_7)$-cycloalkyl, R^{32}—C_uH_{2u}— and Het^3-C_uH_{2u}—, wherein u is an integer selected from the group consisting of 0, 1, 2 and 3;

R^{31} is $(C_1\text{-}C_{10})$-alkyl, which is optionally substituted by one or two identical or different substituents selected from the group consisting of halogen, $(C_3\text{-}C_7)$-cycloalkyl, HO—, $(C_1\text{-}C_6)$-alkyl-O—, $(C_1\text{-}C_6)$-alkyl-$S(O)_m$— and NC—;

R^{32} is selected from the group consisting of phenyl and an aromatic 5-membered or 6-membered monocyclic heterocycle containing one, two or three identical or different ring heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, wherein the phenyl and the heterocycle are optionally substituted by one or more identical or different substituents

selected from the group consisting of halogen, $(C_1$-$C_6)$-alkyl, HO—, $(C_1$-$C_6)$-alkyl-O—, —O—CH_2—O—, —O—CF_2—O—, $(C_1$-$C_6)$-alkyl-$S(O)_m$—, H_2N—$S(O)_2$—, $(C_1$-$C_4)$-alkyl-NH—$S(O)_2$—, di$((C_1$-$C_4)$-alkyl)N—$S(O)_2$—, H_2N—, $(C_1$-$C_6)$-alkyl-NH—, di$((C_1$-$C_6)$-alkyl)N—, $(C_1$-$C_4)$-alkyl-C(O)—NH—, $(C_1$-$C_4)$-alkyl-$S(O)_2$—NH— and NC—, or substituted once by a phenyl ring or $(C_3$-$C_7)$-cycloalkyl ring;

R^{40} is selected from the group consisting of hydrogen and $(C_1$-$C_4)$-alkyl;

or R^{30} and R^{40} together are $(CH_2)_x$ which is optionally substituted by one or more identical or different $(C_1$-$C_4)$-alkyl substituents, wherein x is 2, 3, 4 or 5;

R^{50} is selected from the group consisting of hydrogen, $(C_1$-$C_6)$-alkyl, HO— and $(C_1$-$C_6)$-alkyl-O—;

R^{60} is selected from the group consisting of hydrogen and $(C_1$-$C_6)$-alkyl;

or R^{50} and R^{60} together are $(CH_2)_y$ which is optionally substituted by one or more identical or different $(C_1$-$C_4)$-alkyl substituents, wherein y is 2, 3, 4 or 5;

R^{71} is selected from the group consisting of hydrogen and $(C_1$-$C_8)$-alkyl, which is optionally substituted by one or more identical or different substituents selected from the group consisting of $(C_1$-$C_6)$-alkyl-O— and $(C_1$-$C_6)$-alkyl-C(O)—O—;

R^{72} is selected from the group consisting of hydrogen, $(C_1$-$C_6)$-alkyl, $(C_3$-$C_6)$-cycloalkyl, —CH_2—$(CH_2)_b$—$(C_3$-$C_6)$-cycloalkyl, Het^4 and —$(CH_2)_b$-Het^4, where the alkyl or cycloalkyl is optionally substituted by one or more identical or different substituents selected from the group consisting of halogen, HO—, HOOC—, $(C_1$-$C_6)$-alkyl-O— and $(C_1$-$C_6)$-alkyl-C(O)—O—, NC—, N$((C_1$-$C_4)$-alkyl$)_2$, and b is 0, 1 or 2;

R^{73} is selected from the group consisting of hydrogen and $(C_1$-$C_6)$-alkyl;

or

R^{72} and R^{73}, together with the nitrogen atom to which they are bonded, form a saturated 4-membered to 7-membered monocyclic heterocycle, which contain optionally one further ring heteroatom selected from the group consisting of nitrogen, oxygen and sulfur, which is optionally substituted by one or more identical or different substituents selected from the group consisting of halogen, $(C_1$-$C_4)$-alkyl, HO— and $(C_1$-$C_4)$-alkyl-O—;

Ar, independently of each other group Ar, is selected from the group consisting of phenyl and an aromatic 5-membered or 6-membered monocyclic heterocycle containing one, two or three identical or different ring heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, wherein the phenyl and the heterocycle all are optionally substituted by one or more identical or different substituents selected from the group consisting of halogen, $(C_1$-$C_6)$-alkyl, HO—$(C_1$-$C_6)$-alkyl, Het^4, —$(CH_2)_x$-phenyl, $(C_1$-$C_6)$-alkyl-O—, $(C_3$-$C_7)$-cycloalkyl-$(CH_2)_x$—O—, —CF_3, —CO—$(C_1$-$C_6)$-alkyl, —$NR^{12}R^{13}$, Het^2, —CO—$NR^{12}R^{13}$, CO-Het^2, $(C_1$-$C_6)$-alkyl-$S(O)_m$—, H_2N—$S(O)_2$— and NC—; and wherein phenyl may be substituted by —CH=CH—CH=CH—, —O—CH_2—O—, —O—CH_2—CH_2—O—, —O—CF_2—O— or —N($(C_1$-$C_3)$-alkyl)-CH=CH—;

Het^1, independently of each other group Het^1, is a saturated or unsaturated 4-membered to 8-membered monocyclic heterocycle containing a ring nitrogen atom via which Het^1 is bonded, and optionally, one or two identical or different further ring heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, which is optionally substituted by one or more identical or different substituents selected from the group consisting of halogen, $(C_1$-$C_4)$-alkyl, HO—, $(C_1$-$C_4)$-alkyl-O—, oxo and NC—;

Het^2 is a saturated 4-membered to 7-membered monocyclic heterocycle containing a ring nitrogen atom via which Het^2 is bonded and optionally one further ring heteroatom selected from the group consisting of nitrogen, oxygen and sulfur, which is optionally substituted by one or more identical or different substituents selected from the group consisting of halogen, $(C_1$-$C_4)$-alkyl, HO— and $(C_1$-$C_4)$-alkyl-O—;

Het^3, independently of each other group Het^3, is a saturated 4-membered to 7-membered monocyclic heterocycle containing one or two identical or different ring heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, which is optionally substituted by one or more identical or different substituents selected from the group consisting of fluorine, $(C_1$-$C_4)$-alkyl and oxo;

Het^4, independently of each other group Het^4, is a saturated or unsaturated 4-membered to 8-membered monocyclic heterocycle containing one to four ring heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur which is

optionally substituted by one or more identical or different substituents selected from the group consisting of halogen, (C_1-C_4)-alkyl, HO—, (C_1-C_4)-alkyl-O—, oxo and NC—;

m, independently of each other number m, is 0, 1 or 2;

wherein all cycloalkyl groups, independently of each other, are optionally substituted by one or more identical or different substituents selected from the group consisting of fluorine and (C_1-C_4)-alkyl;

wherein all alkyl, C_sH_{2s}, C_uH_{2u}, $(CH_2)_x$ and $(CH_2)_y$ groups, independently of each other, and independently of any other substituents, are optionally substituted by one or more fluorine substituents.

2. A compound of the formula I in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, as claimed in claim 1, wherein

G is selected from the group consisting of R^{71}—O—C(O)— and R^{72}—N(R^{73})—C(O)—;

R^{30} is R^{32}—C_uH_{2u}—, wherein u is 0 or 1;

R^{32} is selected from the group consisting of phenyl and an aromatic 6-membered monocyclic heterocycle containing one or two nitrogen atoms as ring heteroatoms, wherein the phenyl and the heterocycle are optionally substituted by one or more identical or different substituents selected from the group consisting of halogen, (C_1-C_6)-alkyl, HO—, (C_1-C_6)-alkyl-O—, —O—CH_2—O—, —O—CF_2—O—, (C_1-C_6)-alkyl-S(O)$_m$--, di((C_1-C_4)-alkyl)N—S(O)$_2$—, H_2N—, di((C_1-C_6)-alkyl)N—, (C_1-C_4)-alkyl-C(O)—NH—, and NC—, or substituted once by a phenyl ring; and (C_3-C_7)-cycloalkyl ring;

R^{40} is hydrogen.

3. A compound of the formula I in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, as claimed in claim 1, wherein

G is R^{71}—O—C(O)—;

R^{30} is R^{32}—C_uH_{2u}—, wherein u is 0;


R^{32} is phenyl, wherein the phenyl is optionally substituted by one or more identical or different substituents selected from the group consisting of halogen, (C_1-C_6)-alkyl, HO—, (C_1-C_6)-alkyl-O—, —O—CH_2—O—, —O—CF_2—O—, (C_1-C_6)-alkyl-$S(O)_m$—, di((C_1-C_4)-alkyl)N—$S(O)_2$—, H_2N—, di((C_1-C_6)-alkyl)N—, (C_1-C_4)-alkyl-C(O)—NH—, and NC—, or substituted once by a phenyl ring or (C_3-C_7)-cycloalkyl ring;

and


R^{40} is hydrogen.

4. A compound of the formula I in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, as claimed in claim 1, wherein
R^{50} and R^{60} are both hydrogen.

5. A compound of the formula I in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, as claimed in claim 1, selected from the subformulae:



and



wherein R^1, R^2, R^3, R^4, R^{10}, R^{30}, R^{40}, R^{50}, and R^{60} are as defined in claim 1.

6. A compound of the formula I-1, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, as claimed in claim 5, wherein

R^2 is Ar—C_sH_{2s}—, wherein s is 0;

R^4 is hydrogen; and

R^{10} is hydrogen.

7. A compound of the formula I in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, as claimed in claim 1, wherein

R^{11} is hydrogen or (C_1-C_{10})-alkyl.

8. A compound of the formula I in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, as claimed in claim 1, wherein

R^3 is —O—CH_3.

9. A compound of the formula I, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, as claimed in claim 1, selected from the group consisting of:

(S)-3-[(5-Methoxy-6-phenyl-pyridine-2-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-(2,4-Dichloro-phenyl)-3-[(5-methoxy-6-phenyl-pyridine-2-carbonyl)-amino]-propionic acid

(S)-3-[(6-Chloro-5-methoxy-pyridine-2-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-[(6-Bromo-5-methoxy-pyridine-2-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-{[6-(2-Fluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-[(5-Methoxy-6-phenyl-pyridine-2-carbonyl)-amino]-3-p-tolyl-propionic acid

(S)-3-[(5-Methoxy-6-o-tolyl-pyridine-2-carbonyl)-amino]-3-p-tolyl-propionic acid

(S)-3-{[5-Methoxy-6-(2-trifluoromethyl-phenyl)-pyridine-2-carbonyl]-amino}-3-p-tolyl-propionic acid

(S)-3-{[6-(3-Fluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-p-tolyl-propionic acid

(S)-3-{[5-Methoxy-6-(2-methoxy-phenyl)-pyridine-2-carbonyl]-amino}-3-p-tolyl-propionic acid

(S)-3-{[6-(2-Chloro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-p-tolyl-propionic acid

(S)-3-{[6-(2-Fluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-p-tolyl-propionic acid

(S)-3-{[6-(2,4-Difluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-p-tolyl-propionic acid

(S)-3-{[6-(2,3-Dichloro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-p-tolyl-propionic acid

(S)-3-{[6-(2-Chloro-5-trifluoromethyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-p-tolyl-propionic acid

(S)-3-{[6-(3-Fluoro-2-methyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-(2-fluoro-phenyl)-propionic acid

(S)-3-{[6-(2-Chloro-5-trifluoromethyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-(2-fluoro-phenyl)-propionic acid

(S)-3-{[6-(2,3-Difluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-p-tolyl-propionic acid

(S)-3-{[6-(2,5-Difluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-p-tolyl-propionic acid

(S)-3-{[6-(2,5-Dichloro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-p-tolyl-propionic acid

(S)-3-{[6-(3,5-Dimethyl-isoxazol-4-yl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-p-tolyl-propionic acid

(S)-3-{[6-(4-Fluoro-2-methyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-p-tolyl-propionic acid

(S)-3-{[6-(2,3-Dimethyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-p-tolyl-propionic acid

(S)-3-{[6-(5-Fluoro-2-methyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-p-tolyl-propionic acid

(S)-3-{[6-(4-Fluoro-2-methoxy-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-p-tolyl-propionic acid

(S)-3-{[6-(5-Fluoro-2-methoxy-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-p-tolyl-propionic acid

(S)-3-{[6-(2-Fluoro-5-methyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-p-tolyl-propionic acid

(S)-3-{[6-(3-Chloro-2-methyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-p-tolyl-propionic acid

(S)-3-{[6-(3-Fluoro-2-methyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-p-tolyl-propionic acid

(S)-3-{[6-(5-Chloro-2-fluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-p-tolyl-propionic acid

(S)-3-(2-Fluoro-phenyl)-3-[(5-methoxy-6-phenyl-pyridine-2-carbonyl)-amino]-propionic acid

(S)-3-{[6-(2,4-Dichloro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-(2-fluoro-phenyl)-propionic acid

(S)-3-(2-Fluoro-phenyl)-3-[(5-methoxy-6-o-tolyl-pyridine-2-carbonyl)-amino]-propionic acid

(S)-3-(2-Fluoro-phenyl)-3-{[5-methoxy-6-(2-trifluoromethyl-phenyl)-pyridine-2-carbonyl]-amino}-propionic acid

(S)-3-(2-Fluoro-phenyl)-3-{[5-methoxy-6-(2-methoxy-phenyl)-pyridine-2-carbonyl]-amino}-propionic acid

(S)-3-{[6-(2-Chloro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-(2-fluoro-phenyl)-propionic acid

(S)-3-(2-Fluoro-phenyl)-3-{[6-(2-fluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-propionic acid

(S)-3-{[6-(2,4-Difluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-(2-fluoro-phenyl)-propionic acid

(S)-3-{[6-(2,3-Dichloro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-(2-fluoro-phenyl)-propionic acid

(S)-3-{[6-(2,3-Difluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-(2-fluoro-phenyl)-propionic acid

(S)-3-{[6-(2,5-Difluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-(2-fluoro-phenyl)-propionic acid

(S)-3-{[6-(4-Fluoro-2-methyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-(2-fluoro-phenyl)-propionic acid

(S)-3-{[6-(3,5-Dimethyl-isoxazol-4-yl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-(2-fluoro-phenyl)-propionic acid

(S)-3-{[6-(2,3-Dimethyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-(2-fluoro-phenyl)-propionic acid

(S)-3-[(3,2′-Dimethoxy-[2,3']bipyridinyl-6-carbonyl)-amino]-3-(2-fluoro-phenyl)-propionic acid

(S)-3-{[6-(5-Fluoro-2-methyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-(2-fluoro-phenyl)-propionic acid

(S)-3-{[6-(4-Fluoro-2-methoxy-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-(2-fluoro-phenyl)-propionic acid

(S)-3-{[6-(5-Fluoro-2-methoxy-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-(2-fluoro-phenyl)-propionic acid

(S)-3-{[6-(2-Fluoro-5-methyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-(2-fluoro-phenyl)-propionic acid

(S)-3-{[6-(3-Chloro-2-methyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-(2-fluoro-phenyl)-propionic acid

(S)-3-{[6-(5-Chloro-2-fluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-(2-fluoro-phenyl)-propionic acid

(S)-3-{[6-(3-Chloro-2-fluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-(2-fluoro-phenyl)-propionic acid

(S)-3-(2-Fluoro-phenyl)-3-{[5-methoxy-6-(2-methyl-furan-3-yl)-pyridine-2-carbonyl]-amino}-propionic acid

(S)-3-{[6-(2-Chloro-3-methyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-(2-fluoro-phenyl)-propionic acid

(S)-3-(2-Chloro-phenyl)-3-[(5-methoxy-6-phenyl-pyridine-2-carbonyl)-amino]-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(2,4-dichloro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(4-fluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-propionic acid

(S)-3-{[5-Methoxy-6-(3-trifluoromethyl-phenyl)-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[6-(2,4-Dichloro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[6-(4-Fluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[6-(4-Chloro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-[(5-Methoxy-6-p-tolyl-pyridine-2-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-{[6-(3-Chloro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[5-Methoxy-6-(2-methoxy-phenyl)-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-[(5-Methoxy-6-m-tolyl-pyridine-2-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-{[6-(2-Chloro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[6-(3,4-Difluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[6-(2,5-Difluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[6-(2,5-Dichloro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[6-(3,5-Dimethyl-isoxazol-4-yl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[6-(2,3-Dimethyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[6-(2,4-Dimethyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[6-(4-Fluoro-2-methoxy-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[6-(2-Chloro-5-methyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-(2-Chloro-phenyl)-3-[(6-methoxy-5-o-tolyl-pyridine-3-carbonyl)-amino]-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[5-methoxy-6-(2-methoxy-phenyl)-pyridine-2-carbonyl]-amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-[(5-methoxy-6-m-tolyl-pyridine-2-carbonyl)-amino]-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(2-chloro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(2-fluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(2,4-difluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(2,3-dichloro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(2,3-difluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(2,5-difluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(4-fluoro-2-methyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(2,3-dimethyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-[(3,2′-dimethoxy-[2,3′]bipyridinyl-6-carbonyl)-amino]-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(5-fluoro-2-methyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(4-fluoro-2-methoxy-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-propionic acid

(S)-3-{[6-(4-Chloro-2-methoxy-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-(2-chloro-phenyl)-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(5-fluoro-2-methoxy-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(2-fluoro-5-trifluoromethyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-propionic acid

(S)-3-{[5-Methoxy-6-(2-trifluoromethyl-phenyl)-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[6-(2,4-Difluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[6-(4-Fluoro-2-methyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-[(3,2′-Dimethoxy-[2,3′]bipyridinyl-6-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-[(3′-Fluoro-3-methoxy-[2,4′]bipyridinyl-6-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-{[5-Methoxy-6-(2-methyl-furan-3-yl)-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[6-(4-Cyano-2-fluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(2-fluoro-5-methoxy-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(2-fluoro-5-methyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-propionic acid

(S)-3-{[6-(3-Chloro-2-methyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-(2-chloro-phenyl)-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(3-fluoro-2-methyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-propionic acid

(S)-3-{[6-(5-Chloro-2-fluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]amino}-3-(2-chloro-phenyl)-propionic acid

(S)-3-(2-Chloro-phenyl)-3-[(3′-fluoro-3-methoxy-[2,4’]bipyridinyl-6-carbonyl)-amino]-propionic acid

(S)-3-(2-Chloro-phenyl)-3-[(5-methoxy-6-pyrazin-2-yl-pyridine-2-carbonyl)-amino]-propionic acid

(S)-3-{[6-(3-Chloro-2-fluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-(2-chloro-phenyl)-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[5-methoxy-6-(2-methyl-furan-3-yl)-pyridine-2-carbonyl]-amino}-propionic acid

(S)-3-{[6-(2-Chloro-3-fluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-(2-chloro-phenyl)-propionic acid, and

(S)-3-{[6-(2-Chloro-3-methyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-(2-chloro-phenyl)-propionic acid.

10. A compound of the formula I, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, as claimed in claim 1, selected from the group consisting of:

(S)-3-[(5-Methoxy-6-phenyl-pyridine-2-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-(2,4-Dichloro-phenyl)-3-[(5-methoxy-6-phenyl-pyridine-2-carbonyl)-amino]-propionic acid

(S)-3-({5-Methoxy-6-[3-(5-methyl-[1,3,4]oxadiazol-2-yl)-phenyl]-pyridine-2-carbonyl}-amino)-3-o-tolyl-propionic acid

(S)-3-(2-Chloro-phenyl)-3-[(5-methoxy-6-naphthalen-2-yl-pyridine-2-carbonyl)-amino]-propionic acid

(S)-3-(2-Chloro-phenyl)-3-[(5-methoxy-6-pyrazin-2-yl-pyridine-2-carbonyl)-amino]-propionic acid

(S)-3-(2-Chloro-phenyl)-3-[(6-methoxy-5-naphthalen-2-yl-pyridine-3-carbonyl)-amino]-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[5-methoxy-6-(2-methyl-furan-3-yl)-pyridine-2-carbonyl]-amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(2,3-dimethyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(2-chloro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-propionic acid

(S)-3-(2-Fluoro-phenyl)-3-{[5-methoxy-6-(1,3,5-trimethyl-1H-pyrazol-4-yl)-pyridine-2-carbonyl]-amino}-propionic acid

(S)-3-(2-Fluoro-phenyl)-3-{[5-methoxy-6-(1-methyl-1H-indol-5-yl)-pyridine-2-carbonyl]-amino}-propionic acid

(S)-3-[(5-Methoxy-6-m-tolyl-pyridine-2-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-{[6-(2-Chloro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[6-(3,5-Dimethyl-isoxazol-4-yl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid


(S)-3-{[6-(4-Chloro-phenyl)-5-methoxy-pyridine-2-carbonyl]amino}-3-o-tolyl-propionic acid


(S)-3-{[6-(4-Chloro-phenyl)-5-methoxy-pyridine-2-carbonyl]amino}-3-p-tolyl-propionic acid

(S)-3-{[6-(5-Acetyl-thiophen-2-yl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-(2-chloro-phenyl)-propionic acid, and

(S)-3-{[6-(2-Fluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid.

11. A process for preparing the compound of formula I or a physiologically acceptable salt thereof or a physiologically acceptable solvate of any of them as claimed in claim 1, comprising reacting a compound of the formula II with a compound of the formula III,





wherein the groups A, D, E, L, G, R^{10}, R^{30}, R^{40}, R^{50} and R^{60} in the compounds of the formulae II and III are defined as in the compounds of the formula I and additionally functional groups can be present in protected form or in the form of a precursor group, and the group 3 in the compound of the formula II is HO—, (C_1-C_4)-alkyl-O— or halogen.

12. A pharmaceutical composition comprising the compound of claim 1 or a physiologically acceptable salt thereof or a physiologically acceptable solvate of any of them.

13. The pharmaceutical composition of claim 12, further comprising a pharmaceutically acceptable carrier.